1 neuroprotective effect of quince leaf hydroalcoholic extract on intracerebroventricular streptozotocin-induced oxidative stress in cortical tissue of rat brain

2 Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

3 Cholinesterase inhibitors for Alzheimer's disease

4 Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease.

5 Cholinesterase inhibitors as Alzheimer's therapeutics (Review).

6 Reconsideration of anticholinesterase therapeutic strategies against alzheimer's disease

7 Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease.

8 Synthesis and biological evaluation of flavone-8-acrylamide derivatives as potential multi-target-directed anti Alzheimer agents and investigation of binding mechanism with acetylcholinesterase.

9 Discovery of N-methylpiperazinyl flavones as a novel class of compounds with therapeutic potential against Alzheimer's disease: Synthesis, binding affinity towards amyloid β oligomers (Aβo) and ability to disrupt Aβo-PrP C interactions

10 Protection of cholinergic and antioxidant system contributes to the effect of Vitamin D3 ameliorating memory dysfunction in sporadic dementia of Alzheimer's type

11 Investigation of the Effects of Biochemical Parameters on Alzheimer's Disease.

12 Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships

13 Biomarkers for Alzheimer’s Disease in Saliva: A Systematic Review

14 Immunosenescence of Natural Killer Cells, Inflammation, and Alzheimer’s Disease

15 Impaired Cerebral Vasomotor Reactivity in Alzheimer’s Disease

16 Development of Regional Disparities in Alzheimer’s Disease Mortality in the Slovak Republic from 1996 to 2015

17 Physician Practice Patterns Associated with Diagnostic Evaluation of Patients with Suspected Mild Cognitive Impairment and Alzheimer’s Disease

18 Longitudinal brain atrophy patterns and neuropsychological performance in older adults with HIV-associated neurocognitive disorder compared with early Alzheimer's disease.

19 The Model of Aging Acceleration Network Reveals the Correlation of Alzheimer's Disease and Aging at System Level.

20 Early Alzheimer's disease-type pathology in the frontal cortex of wild mountain gorillas (Gorilla beringei beringei).

21 Fecal metabolite of a gnotobiotic mouse transplanted with gut microbiota from a patient with Alzheimer's disease.

22 Visual perceptual disorders in Alzheimer's disease.

23 Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.

24 Meta-Analysis of Gene Expression and Identification of Biological Regulatory Mechanisms in Alzheimer's Disease.

25 Corrigendum to “Fuzzy adaptive cognitive stimulation therapy generation for Alzheimer's sufferers: Towards a pervasive dementia care monitoring platform” (Future Generation Computer Systems (2018) 88 (479–490), (S0167739X1830089X) (10.1016/j.future.2018.06.018))

26 Promoter Polymorphism-219T/G is an Effect Modifier of the Influence of ε4 on Alzheimer's Disease Risk in a Multiracial Sample.

27 Advance of sporadic Alzheimer's disease animal models.

28 Evaluation of the Music Engagement Program for people with Alzheimer's disease and dementia: Study protocol for a pilot trial.

29 Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions.

30 Molecular Inverse Comorbidity between Alzheimer's Disease and Lung Cancer: New Insights from Matrix Factorization.

31 Vitamin D concentration and risk of Alzheimer disease: A meta-analysis of prospective cohort studies.

32 The "rights" of precision drug development for Alzheimer's disease.

33 Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer's disease.

34 Current State of Digital Biomarker Technologies for Real-Life, Home-Based Monitoring of Cognitive Function for Mild Cognitive Impairment to Mild Alzheimer Disease and Implications for Clinical Care: Systematic Review.

35 Radiosynthesis of carbon-11 labeled PDE5 inhibitors as new potential PET radiotracers for imaging of Alzheimer's disease.

36 Dynamic structural determinants underlie the neurotoxicity of the N-terminal tau 26-44 peptide in Alzheimer's disease and other human tauopathies.

37 White matter alterations in early-stage Alzheimer's disease: A tract-specific study.

38 Risk estimation before progression to mild cognitive impairment and Alzheimer's disease: an AD resemblance atrophy index.

39 Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease.

40 Is Low Psychomotor Speed a Marker of Brain Vulnerability in Late Life? Digit Symbol Substitution Test in the Prediction of Alzheimer, Parkinson, Stroke, Disability, and Depression.

41 Prediction of Alzheimer's disease based on deep neural network by integrating gene expression and DNA methylation dataset

42 Investigation of Cerebral Hemodynamic Changes in Mild Cognitive Impairment Due to Alzheimer’s Disease During a Verbal Fluency Task

43 Automatic detection of alzheimer disease based on histogram and random forest

44 Dysfunction of the ubiquitin ligase E3A Ube3A/E6-AP contributes to synaptic pathology in Alzheimer’s disease

45 Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

46 Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

47 Visualizing Alzheimer’s Disease Mouse Brain with Multispectral Optoacoustic Tomography using a Fluorescent probe, CDnir7

48 Synaptic and memory dysfunction in a β-amyloid model of early Alzheimer's disease depends on increased formation of ATP-derived extracellular adenosine

49 Possible epigenetic regulatory effect of dysregulated circular RNAs in Alzheimer’s disease model

50 Blockade of α4 integrins reduces leukocyte–endothelial interactions in cerebral vessels and improves memory in a mouse model of Alzheimer’s disease

51 Serum and brain natural copper stable isotopes in a mouse model of Alzheimer’s disease

52 Defective autophagy and Alzheimer's disease: Is calcium the key?

53 Differentiating between Alzheimer's disease, amnestic mild cognitive impairment, and normal aging via diffusion kurtosis imaging

54 Optogenetics-induced activation of glutamate receptors improves memory function in mice with Alzheimer's disease

55 Glucocorticoid receptors modulate dendritic spine plasticity and microglia activity in an animal model of Alzheimer's disease

56 Fecal microbiota transplantation alleviated Alzheimer’s disease-like pathogenesis in APP/PS1 transgenic mice

57 Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer’s disease are not present in diabetic Alzheimer’s disease

58 Reversibility of Age-related Oxidized Free NADH Redox States in Alzheimer’s Disease Neurons by Imposed External Cys/CySS Redox Shifts

59 The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease

60 Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model

61 Acute restraint stress reverses impaired LTP in the hippocampal CA1 region in mouse models of Alzheimer’s disease

62 Screening older adults for amnestic mild cognitive impairment and early-stage Alzheimer’s disease using upper-extremity dual-tasking

63 Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer’s disease

64 Electroencephalography reveals lower regional blood perfusion and atrophy of the temporoparietal network associated with memory deficits and hippocampal volume reduction in mild cognitive impairment due to Alzheimer’s disease

65 A comment on effect of plant extracts on Alzheimer′s disease: An insight into therapeutic avenues

66 Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction a 6 month follow up

67 Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease

68 Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimer's Disease?

69 Somatic mutation that affects transcription factor binding upstream of CD55 in the temporal cortex of a late-onset Alzheimer disease patient.

70 Commentary: Donepezil enhances understanding of degraded speech in Alzheimer's disease

71 CBIR system using Capsule Networks and 3D CNN for Alzheimer's disease diagnosis

72 Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid.

73 Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.

74 Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases.

75 Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches

76 Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging.

77 "Muscle-Gut-Brain Axis": Can Physical Activity Help Patients with Alzheimer's Disease Due to Microbiome Modulation?

78 Toward common mechanisms for risk factors in Alzheimer's syndrome.

79 Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design.

80 Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid.

81 Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer’s disease

82 Polygenic impact of common genetic risk loci for Alzheimer’s disease on cerebral blood flow in young individuals

83 Plasma cortisol is associated with cerebral hypometabolism across the Alzheimer's disease spectrum.

84 Impact of Anti-Dementia Medication on the Risk of Death and Causes of Death in Alzheimer's Disease.

85 Enhancement of tripartite synapses as a potential therapeutic strategy for Alzheimer's disease: a preclinical study in rTg4510 mice.

86 Overview of Transgenic Mouse Models for Alzheimer's Disease.

87 Time to test antibacterial therapy in Alzheimer's disease.

88 Cognitive decline in normal aging and early Alzheimer’s disease: A continuous or discontinuous transition? A historical review and future research proposal

89 Exposure to general anesthesia and risk of alzheimer's disease: a systematic review and meta-analysis

90 Diagnostic value of digital clock drawing test in comparison with CERAD neuropsychological battery total score for discrimination of patients in the early course of Alzheimer’s disease from healthy individuals

91 Correction: Curcumin-Loaded Nanoparticles Potently Induce Adult Neurogenesis and Reverse Cognitive Deficits in Alzheimers Disease Model via Canonical Wnt/-Catenin Pathway (ACS Nano (2014) 8:1 (76-103) DOI: 10.1021/nn405077y)

92 Vitamin Supplementation as an Adjuvant Treatment for Alzheimer's Disease.

93 Restoration of Olfactory Memory in Overexpressing Human Alzheimer's Disease Associated Tau by Manipulation of L-Type Ca Channels.

94 Sleep experiences during different lifetime periods and in vivo Alzheimer pathologies.

95 No relationship between fornix and cingulum degradation and within-network decreases in functional connectivity in prodromal Alzheimer's disease.

96 Regional brain atrophy predicts time to conversion to Alzheimer's disease, dependent on baseline volume.

97 Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.

98 Synthesis of novel chromenones linked to 1,2,3-triazole ring system: Investigation of biological activities against Alzheimer's disease

99 Radiosynthesis of a carbon-11 labeled tetrahydrobenzisoxazole derivative as a new PET probe for γ-secretase imaging in Alzheimer's disease.

100 Extracorporeal apheresis therapy for Alzheimer disease-targeting lipids, stress, and inflammation.

101 Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer's Disease.

Keyword Connections

Journals

Research Groups

Bibliographies